

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Julie Straub, Howard Bernstein, Donald E. Chickering, III, Sarwat Khattak, and

Greg Randall

Serial No.:

09/706,045

Art Unit:

1617

Filed:

November 3, 2000

Examiner:

E. J. Webman

For:

POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF

Assistant Commissioner for Patents Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit a Supplemental Information Disclosure Statement, including one (1) page of Form PTO-1449, and copies of the two (2) documents cited therein.

It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 50-1868.

U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	Class/Subclass
4,818,542	04-04-1989	DeLuca, et al.	424/491
6,565,885	05-20-2003	Tarara, et al.	424/489

U.S.S.N.:

09/706,045

Filed:

November 3, 2000

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,

Rivka D. Monheit

Reg. No. 48,731

Dated: June 23, 2003

HOLLAND & KNIGHT LLP One Atlantic Center 1201 West Peachtree Street, N.E. Suite 2000 Atlanta, Georgia 30309-3400 404-817-8473 FAX 404-817-8588 www.hklaw.com